Abstract
It was a milestone of cancer therapy in general when Huggins et al. [1] in 1941 first reported the beneficial clinical effects of bilateral orchiectomy in patients with prostate cancer, and the use of castration or estrogens as standard therapy remained the first- line treatment for many years. It was furthermore the beginning of a development which, over the following decades, led to the manipulation of testicular androgen synthesis and to attempts to eliminate other possible sources of male hormones.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Huggins C, Stevens Jr RE, Hodges CV: Studies on prostatic cancer: effects of castration on advanced carcinoma of prostate gland. Arch Surg 1941 (43):209–223
Huggins C, Scott WW: Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17- ketosteroids and estrogen. Ann Surg 1945 (122):1031–1041
Scott WW: Endocrine management of disseminated prostate cancer, including bilateral adrenalectomy and hypophysectomy. Trans Am Ass GU Surg 1953 (44):101–104
Hughes SWM, Burley DM: Aminoglutethimide: a ‘side effect’ turned to a therapeutic advantage. Postgrad Med J 1970 (46):409–417
Mackler MA, Liberti JP, Smith MJV, Koontz WW, Prout GR: The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 1972 (9):423–425
Sanford EJ, Paulson DF, Rohner Jr TJ, Santen RJ, Bardin CW: The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol 1977 (118):1019–1021
Walsh PC: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 1975 (2):125–140
Stone AR, Hargreave TB, Chisholm GD: The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer. Br J Urol 1980 (52):535–538
Fossa SD, Jahnsen JU, Karlsen S, Ogreid P, Haveland H, Trovag A: High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. Eur Urol 1985 (11):11–16
Van Erps P, Denis L, Nowé P, Keuppens F: Diethylstilbestrol diphosphate in the treatment of prostatic cancer in relapse. In: Denis L, Murphy GP, Prout GR, Schroder FH (eds) Controlled Clinical Trials in Urologic Oncology. Raven Press, New York 1984
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Jacobi, G.H. (1988). Second-Line Endocrine Treatment. In: Denis, L. (eds) The Medical Management of Prostate Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73238-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-73238-6_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73240-9
Online ISBN: 978-3-642-73238-6
eBook Packages: Springer Book Archive